Residue Phe42 is critical for the catalytic activity of Escherichia coli major nitroreductase NfsA

Biotechnology Letters

Volumn 35, Issue 10, 2013, Pages 1693-1700

  Yang, Jun ^a,b   Zhan, Junfei ^a   Bai, Jing ^a   Liu, Peiyu ^a   Xue, Yingjiao ^a   Yang, Qing ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b Dalian SEM Bioengineer and Biotech Ltd   (China)

Author keywords

Escherichia coli nitroreductase; Gene directed enzyme prodrug therapy; Site directed mutagenesis

Indexed keywords

CONFORMATIONAL CHANGE; ENZYME-PRODRUG THERAPIES; HELIX CONTENT; NITROREDUCTASES; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; STRUCTURAL COMPARISON; STRUCTURAL FEATURE;

AROMATIC COMPOUNDS; GENE THERAPY; SPECTRUM ANALYSIS;

ESCHERICHIA COLI;

ESCHERICHIA COLI;

ESCHERICHIA COLI PROTEIN; MUTANT PROTEIN; NFSA PROTEIN, E COLI; NITROREDUCTASE;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; KINETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; CATALYTIC DOMAIN; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; NITROREDUCTASES; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

EID: 84884818566     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-013-1262-y     Document Type: Article

References (16)

1. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ (1992) The bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol l44: 2289-2295.
2. Friedlos F, Court S, Ford M, Denny WA, Springer C (1998) Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther 5(1): 105-112.
3. Grove JI, Lovering AL, Guise C, Race PR, Wrighton CJ, White SA, Hyde EI, Searle PF (2003) Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res 63: 5532-5537.
4. Haynes CA, Koder RL, Miller AF, Rodgers DW (2002) Structures of nitroreductase in three states. J Biol Chem 277: 11513-11520.
5. Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, Hyde EI, Searle PF (2010) Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochem Pharmacol 79: 102-111.
6. Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM (1992) The bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)II. A comparison of an Eschericia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 44: 2297-2301.
7. Kobori T, Sasaki H, Lee WC, Zenno S, Saigo K, Murphy ME, Tanokura M (2001) Structure and site-directed mutagenesis of a flavoprotein from Escherichia coli that reduces nitrocompounds: alteration of pyridine nucleotide binding by a single amino acid substitution. J Biol Chem 276: 2816-2823.
8. Lovering AL, Hyde EI, Searle PF, White SA (2001) The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1. 7 Å, 1. 8 Å and 2. 4 Å resolution. J Mol Biol 309: 203-213.
9. María DR, Pérez-Reinado E, Castillo F, Moreno-Vivián C (2008) Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev 32: 474-500.
10. Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF (2010) Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol 79: 678-687.
11. Race PR, Lovering AL, Green RM, Ossor A, White SA, Searle PF, Wrighton CJ, Hyde EI (2005) Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone. J Biol Chem 280: 13256-13264.
12. Race PR, Lovering AL, White SA, Grove JI, Searle PF, Wrighton CW, Hyde EI (2007) Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J Mol Biol 368: 481-492.
13. San KY, Bennett GN, Berrios-Rivera SJ (2002) Metabolic engineering through cofactor manipulation and its effects on metabolic flux redistribution in Escherichia coli. Metab Eng 4: 182-192.
14. Vass SO, Jarrom D, Wilson WR, Hyde EI, Searle PF (2009) E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954. Brit J Cancer 100: 1903-1911.
15. Zenno S, Koike H, Kumar AN, Jayaraman R, Tanokura M, Saigo K (1996) Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol 178: 4508-4514.
16. Zigansbin AM, Gerlacb R, Borch T, Naumov AV, Naumova RP (2007) Production of eight different bydride complexes and nitrite release from 2, 4, 6-trinitrotoluene by Yarrowia lipolytica. Appl Environ Microb 73(24): 7898-7905.